<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Aspirin inhibits both the cyclooxygenase (COX)-1-dependent production of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> (<z:chebi fb="0" ids="15627">TXA2</z:chebi>) in platelets and COX-2-dependent production of anti-aggregatory <z:chebi fb="0" ids="15552">prostaglandin I2</z:chebi> (<z:chebi fb="0" ids="15552">PGI2</z:chebi>) in vessel walls, resulting in "aspirin dilemma." Our objective is to investigate whether ASP6537 can overcome aspirin dilemma and exert a potent antithrombotic effect without a concurrent ulcerogenic effect </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We evaluated the inhibitory effects of ASP6537 on recombinant human COX-1 (rhCOX-1) and rhCOX-2 activities using a COX-1/2 selectivity test </plain></SENT>
<SENT sid="2" pm="."><plain>To determine whether ASP6537 induces aspirin dilemma, we examined the effects of ASP6537 on in vitro <z:chebi fb="0" ids="15627">TXA2</z:chebi> and <z:chebi fb="0" ids="15552">PGI2</z:chebi> metabolite production from platelets and isolated aorta of guinea pigs, and on plasma concentrations of <z:chebi fb="0" ids="15627">TXA2</z:chebi> and <z:chebi fb="0" ids="15552">PGI2</z:chebi> metabolites in aged rats </plain></SENT>
<SENT sid="3" pm="."><plain>Finally, we evaluated the antithrombotic effects and ulcerogenic activity of ASP6537 using an electrically induced carotid <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> model and a <z:hpo ids='HP_0002592'>gastric ulcer</z:hpo> model in guinea pigs </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The IC50 ratios of rhCOX-2 to rhCOX-1 for ASP6537 and aspirin were &gt;142,000 and 1.63 fold, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>ASP6537 inhibited <z:chebi fb="0" ids="15627">TXA2</z:chebi> production more selectively than aspirin in in vitro and in vivo <z:chebi fb="0" ids="15627">TXA2</z:chebi>/<z:chebi fb="0" ids="15552">PGI2</z:chebi> production studies </plain></SENT>
<SENT sid="6" pm="."><plain>ASP6537 exerted a significant antithrombotic effect at ≥3mg/kg, while aspirin tended to inhibit <z:mp ids='MP_0005048'>thrombosis</z:mp> at 300mg/kg but it was not statistically significant </plain></SENT>
<SENT sid="7" pm="."><plain>Further, ASP6537 did not induce <z:mpath ids='MPATH_579'>ulcer</z:mpath> formation at 100mg/kg, whereas aspirin exhibited an ulcerogenic effect at doses of ≥100mg/kg </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: ASP6537 functions as a highly selective COX-1 inhibitor with a superior ability to aspirin for normalizing <z:chebi fb="0" ids="15627">TXA2</z:chebi>/<z:chebi fb="0" ids="15552">PGI2</z:chebi> balance, and exerts antithrombotic effect without ulcerogenic effect </plain></SENT>
</text></document>